Standard of Care Treatment: Managing Inflammation

Because A20 Haploinsufficiency (HA20) is so rare, there is no single, universal “recipe” for treatment. Instead, your medical team will create a plan based on your or your child’s specific phenotype (how the disease shows up in the body) and the specific organs affected ^[1][2]. The ultimate goal is to achieve control of fever and organ inflammation, aiming to be largely free of debilitating fevers, ulcers, and pain ^[3].

A Phenotype-Guided Approach

Treatment evidence is largely from case reports, small observational cohorts, and extrapolation from related diseases, meaning many medications may be prescribed “off-label,” especially in children.

Maintenance Medications

For individuals with less frequent fevers or manageable mouth sores, doctors often consider oral medications:

• Colchicine: This is sometimes used as a first-line treatment. However, its effectiveness varies significantly. In one study of 17 children, about 40% found relief with colchicine alone, while other reviews suggest it may work for only about 24% of patients ^[4][5]. These figures come from small, heterogeneous groups and do not guarantee an individual response.
• PDE4 Inhibitors: In some cases, medications like apremilast may be considered, though there is less data on their use specifically in children with HA20 ^[1].

Targeted Biologics

If colchicine isn’t appropriate, or if a person has severe symptoms like intestinal inflammation or debilitating joint pain, doctors move to “targeted” therapies ^[1]. These are often called biologics because they are engineered proteins that block specific parts of the immune system.

• TNF Inhibitors: These medications (such as adalimumab or infliximab) block a protein called TNF-α, which is highly active in HA20 ^[6]. While small pediatric cohorts reported efficacy (e.g., 60% for adalimumab and 100% for infliximab in one 17-patient group), these numbers come from very small case series and should not be used to predict your individual outcome ^[4].
• IL-1 Inhibitors: Medications like anakinra block Interleukin-1, another major driver of inflammation. These are often used when fevers and “systemic” inflammation are the main problems ^[7][3].
• JAK Inhibitors: These are a newer class of oral medications that block multiple inflammatory signals at once. They are generally considered when the disease hasn’t responded to other treatments ^[6][1].

Managing Flares with Corticosteroids

Corticosteroids (like prednisone) are powerful anti-inflammatory drugs occasionally used to quickly “quench the fire” during a severe flare ^[8]. While they work rapidly, they are usually not used as a long-term solution due to side effects like growth suppression and bone thinning in children. Instead, they serve as a “bridge” while waiting for other medications to take effect ^[9].

Why Consistency is Critical

It is vital to never stop or change your immunosuppressive medication without a doctor’s guidance. While prolonged corticosteroids may require a supervised taper and a sick-day plan, biologics and JAK inhibitors are generally held rather than tapered during serious infections or around surgery. Continuing an immune-modifying drug during an infection can be dangerous, but abruptly stopping effective therapy without guidance can precipitate a flare ^[1][10]. Follow a specific written plan for your drug.

When Treatment Stops Working (Secondary Failure)

Sometimes, a medication that worked well for months or years begins to lose its effectiveness. This is known as secondary failure ^[6].

• Causes of Failure: Loss of response can reflect underdosing, non-adherence, an infection, a new disease manifestation, or anti-drug antibodies (where the body creates antibodies to neutralize the biologic) ^[6].
• Management Strategies: If a medication fails, the team may check the levels of the drug in the blood, adjust the dose, or switch to a different class of medication, representing an individualized specialist decision rather than a standard sequence ^[6][11].

Monitoring for Safety

Because these medications “turn down” the immune system, patients may be at a higher risk for certain infections ^[3]. Safety monitoring differs by drug:

• Before starting TNF or JAK inhibitors, screening for tuberculosis (TB) and hepatitis is typically required ^[1][4].
• Avoid live vaccines while on biologics ^[1].
• Colchicine has important renal, hepatic, hematologic, and drug-interaction considerations.
• You or your child will need regular blood tests to check blood counts (CBC), liver function, and inflammatory markers (like CRP) to ensure the specific treatment class is both safe and effective ^[1][4].